全文获取类型
收费全文 | 288468篇 |
免费 | 46670篇 |
国内免费 | 13367篇 |
专业分类
耳鼻咽喉 | 6414篇 |
儿科学 | 6865篇 |
妇产科学 | 3934篇 |
基础医学 | 18312篇 |
口腔科学 | 4319篇 |
临床医学 | 45850篇 |
内科学 | 65526篇 |
皮肤病学 | 8544篇 |
神经病学 | 21741篇 |
特种医学 | 11471篇 |
外国民族医学 | 73篇 |
外科学 | 53579篇 |
综合类 | 27816篇 |
现状与发展 | 105篇 |
一般理论 | 14篇 |
预防医学 | 17133篇 |
眼科学 | 7330篇 |
药学 | 16544篇 |
186篇 | |
中国医学 | 10052篇 |
肿瘤学 | 22697篇 |
出版年
2024年 | 972篇 |
2023年 | 6897篇 |
2022年 | 7022篇 |
2021年 | 11132篇 |
2020年 | 12087篇 |
2019年 | 6942篇 |
2018年 | 12357篇 |
2017年 | 11860篇 |
2016年 | 12627篇 |
2015年 | 15169篇 |
2014年 | 23716篇 |
2013年 | 23154篇 |
2012年 | 16557篇 |
2011年 | 17796篇 |
2010年 | 18624篇 |
2009年 | 20910篇 |
2008年 | 13651篇 |
2007年 | 11718篇 |
2006年 | 14018篇 |
2005年 | 10753篇 |
2004年 | 7631篇 |
2003年 | 6351篇 |
2002年 | 5764篇 |
2001年 | 6851篇 |
2000年 | 5872篇 |
1999年 | 5868篇 |
1998年 | 5344篇 |
1997年 | 5076篇 |
1996年 | 4647篇 |
1995年 | 4379篇 |
1994年 | 2931篇 |
1993年 | 2184篇 |
1992年 | 2045篇 |
1991年 | 1972篇 |
1990年 | 1590篇 |
1989年 | 1637篇 |
1988年 | 1393篇 |
1987年 | 1160篇 |
1986年 | 1128篇 |
1985年 | 900篇 |
1984年 | 635篇 |
1983年 | 574篇 |
1982年 | 552篇 |
1981年 | 437篇 |
1980年 | 384篇 |
1979年 | 328篇 |
1978年 | 328篇 |
1977年 | 396篇 |
1975年 | 277篇 |
1972年 | 302篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
11.
12.
Yuxiang Ma Wenfeng Fang Hongyun Zhao Sai Praneeth Bathena Amol Tendolkar Jennifer Sheng Li Zhang 《The oncologist》2021,26(4):e549-e566
Lessons Learned
- The overall safety profiles of ipilimumab 3 mg/kg and 10 mg/kg administered every 3 weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies. No new safety signals were identified.
- The mean systemic exposures to ipilimumab (assessed by first dose area under the curve during the dosing interval and maximum serum concentration) were numerically lower in the Chinese patient population than in U.S. patients for both 3 mg/kg and 10 mg/kg doses; however, the range of serum concentrations in the Chinese and U.S. populations overlapped (3 mg/kg and 10 mg/kg), suggesting that ipilimumab pharmacokinetics was ethnically insensitive in this study.
13.
Bortezomib is a novel proteasome inhibitor, which has been successfully used to treat mantle cell lymphoma and multiple myeloma. However, the direct effects of bortezomib on acute promyelocytic leukaemia (APL) have not been fully investigated. In the present study, the WST-8 assay, western blotting, flow cytometry, monodansylcadaverine staining and transmission electron microscopy were performed. It was demonstrated that bortezomib treatment induced a time- and dose-dependent decrease in the viability of NB4 cells. Bortezomib treatment induced cell apoptosis in NB4 cells, as assessed by Annexin V/propidium iodide analysis, and the detection of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase, Bax and Bcl-2 expression. Furthermore, bortezomib treatment induced autophagy in NB4 cells, as indicated by autophagosome formation, p62 degradation, LC3-I to LC3-II conversion and formation of acidic autophagic vacuoles. Notably, autophagy induced by bortezomib was initiated prior to apoptosis. Inhibition of autophagy by knocking down Beclin-1 expression increased bortezomib-induced apoptosis in NB4 cells. Therefore, the present study revealed that the combination of bortezomib and autophagy inhibition may be a potential treatment strategy for APL. 相似文献
14.
“三全育人”视角下思政教育机制实践与探索——“杏林成长导师”计划的构建 《医学教育管理》2021,7(6):656-660
“三全育人”是高校思政教育工作的关键一环,也是中医药高校推动思政教育的重要内容。以“三全育人”为视角对北京中医药大学思想政治教育举措“杏林成长导师”计划路径、内容深入分析,运用统计分析和文献研究方法,剖析该计划对中医学专业大学生的学业、思想和实践等多个层面的现实成效,从而为“三全育人”理念在中医药院校制度建构中的应用提供新的视角与方法。 相似文献
15.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
16.
17.
18.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
19.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
20.